DUBLIN, Nov. 14,
2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical
company, today announced that Siggi
Olafsson, President and Chief Executive Officer, will
present at Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 a.m. GMT/4:30 a.m.
ET.
Individuals who cannot attend the meeting in person can find
webcast information
at:https://wsw.com/webcast/jeff315/mnk/1699320. A
replay will also be available following the meeting.
ABOUT MALLINCKRODT
Mallinckrodt is a global business
consisting of multiple wholly owned subsidiaries that develop,
manufacture, market and distribute specialty pharmaceutical
products and therapies. The Company's Specialty Brands reportable
segment's areas of focus include autoimmune and rare diseases in
specialty areas like neurology, rheumatology, hepatology,
nephrology, pulmonology, ophthalmology and oncology; immunotherapy
and neonatal respiratory critical care therapies; analgesics; and
gastrointestinal products. Its Specialty Generics reportable
segment includes specialty generic drugs and active pharmaceutical
ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the Company in advance of or in
lieu of distributing a press release or a filing with the SEC
disclosing the same information. Therefore, investors should look
to the Investor Relations page of the website for important and
time-critical information. Visitors to the website can also
register to receive automatic e-mail and other notifications
alerting them when new information is made available on the
Investor Relations page of the website.
CONTACTS
Investor Relations
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag / Aaron
Palash / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. Other brands are
trademarks of a Mallinckrodt company or
their respective owners. © 2024.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-jefferies-london-healthcare-conference-302305741.html
SOURCE Mallinckrodt plc
